（文章来源：每日经济新闻） 每经AI快讯，港股创新药板块继续走强，亚盛医药-B涨逾10%，康诺亚-B、乐普生物-B涨逾7%，诺诚 健华、信达生物涨超5%。 ...

Group 1 - The Hong Kong biotechnology stocks collectively rose, with notable increases in several companies' stock prices [1][2] - Beihai Kangcheng-B saw a rise of nearly 19%, while other companies like Gilead Sciences-B and Ascentage Pharma-B also experienced significant gains of over 15% and 9% respectively [1][2] - The overall trend indicates a positive sentiment in the biotechnology sector, with multiple companies achieving gains of over 5% [1][2] Group 2 - Specific stock performance includes: Beihai Kangcheng-B at 18.99% increase, Gilead Sciences-B at 15.30%, and Ascentage Pharma-B at 9.48% [2] - The market capitalization of these companies varies significantly, with Gilead Sciences-B at approximately 11.477 billion and Ascentage Pharma-B at about 29.86 billion [2] - Other notable performers include Jiahua Bio-B and Beikang Medical-B, both showing increases of over 7% [1][2]

恒生生物科技指数大涨超2%。指数成份股中，亚盛医药B（06855）涨超8%；康诺亚-B（02162）涨 7%；信达生物涨5%。 钢铁股涨幅居前，上半年钢铁行业盈利大幅增长，机构称长期看产能治理仍是主线。马鞍山钢铁股份 (00323)超涨10%；鞍钢股份(00347)涨5%。 心动公司(02400)盈喜后大涨24%，预计上半年净利润同比增长约215%。 华虹半导体(01347)再涨超6%，北美客户PMIC需求高增带动业绩，新资产收购预计一年内完成。 正乾金融控股(01152)复牌飙升逾300%，午盘收涨224%。向债权人发行可换股债偿还债务。 和誉-B(02256)绩后涨5%，中期纯利同比增长58.8%至3.28亿，公司年内持续回购股份。 智通财经获悉，港股恒生指数涨0.27%，涨66点，报24799点；恒生科技指数涨0.33%。港股早盘成交 1124亿港元。 东方甄选(01797)涨超15%，近一个月股价实现翻倍，机构建议关注公司向产品驱动的转型。 中船防务(00317)再涨超6%，中国船舶吸收合并中国重工方案获批，公司未来有望参与整合。 蓝思科技(06613)涨超4%，超额配股权获悉数行使，昨日起正式进入港 ...

智通财经APP获悉，港股恒生指数涨0.27%，涨66点，报24799点；恒生科技指数涨0.33%。港股早盘成 交1124亿港元。 恒生生物科技指数大涨超2%。指数成份股中，亚盛医药B（06855）涨超8%；康诺亚-B（02162）涨 7%；信达生物涨5%。 钢铁股涨幅居前，上半年钢铁行业盈利大幅增长，机构称长期看产能治理仍是主线。马鞍山钢铁股份 (00323)超涨10%；鞍钢股份(00347)涨5%。 心动公司(02400)盈喜后大涨24%，预计上半年净利润同比增长约215%。 华虹半导体(01347)再涨超6%，北美客户PMIC需求高增带动业绩，新资产收购预计一年内完成。 正乾金融控股(01152)复牌飙升逾300%，午盘收涨224%。向债权人发行可换股债偿还债务。 东方甄选(01797)涨超15%，近一个月股价实现翻倍，机构建议关注公司向产品驱动的转型。 中船防务(00317)再涨超6%，中国船舶吸收合并中国重工方案获批，公司未来有望参与整合。 蓝思科技(06613)涨超4%，超额配股权获悉数行使，昨日起正式进入港股通名单。 东软睿新集团(09616)盈警后跌超15%，预计中期股东应占利润下降约20%-3 ...

Group 1 - The core point of the news is the performance of the Zhongyin Innovation Medical Mixed C Fund, which has shown significant returns over various time frames, with a year-to-date return of 80.47% and a recent one-month return of 10.05% [1] - As of June 30, 2025, the fund's total assets amounted to 2.686 billion yuan, indicating a substantial scale for a fund established in October 2020 [1] - The top ten stock holdings of the fund account for a combined 62.83%, with notable investments in companies such as Innovent Biologics (8.33%) and Hengrui Medicine (8.08%) [1] Group 2 - The fund manager, Zheng Ning, has a strong background in the investment industry, having previously held senior positions at Taikang Asset Management and Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed Fund since July 1, 2022, and has also taken on managerial roles for other funds within the Zhongyin family [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康諾亞生物醫藥科技有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02162 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | 本月底法定/註冊股本總額： ...

Core Insights - The Chinese innovative pharmaceutical industry is experiencing significant growth, with a record-breaking $60.5 billion licensing agreement between 3SBio and Pfizer, marking a milestone in China's innovative drug transactions [1] - In the first half of 2025, over 50 global collaborations were established in the Chinese innovative drug sector, totaling $48.448 billion, alongside 154 new drug clinical approvals and 16 innovative drugs successfully launched [2][3] - The Hong Kong innovative drug ETF has seen a remarkable year-to-date increase of 58.95%, outperforming the Hang Seng Index and technology index [1] Industry Developments - The number of new drug clinical approvals reached 154 in June 2025, a 9% increase from the previous month, with bispecific antibodies and ADC drugs becoming the core areas of technological breakthroughs [2] - The Chinese innovative drug sector is transitioning from a "pharmaceutical giant" to a "pharmaceutical powerhouse," with the number of original innovative drugs in development now ranking first globally [2][3] - The introduction of a "commercial health insurance innovative drug directory" by the National Healthcare Security Administration is expected to create new payment channels for high-priced innovative drugs [3][4] Market Trends - The proportion of oncology pipeline transactions has decreased from 72% in 2023 to 61% in 2024, while the share of metabolic endocrine and autoimmune fields has increased to 25% [3] - The domestic innovative drug self-pay market is projected to grow from 320 billion yuan in 2024 to 1 trillion yuan by 2030, providing ample space for high-priced innovative drugs [3][4] Financial Performance - The proportion of R&D expenditure relative to revenue for innovative drug companies has decreased from 157% in 2023 to 89% currently, with some companies achieving net profit margins of 15% to 20% [5][6] - The top ten weighted stocks in the Hong Kong innovative drug selection index account for 75.85% of the index, indicating a concentration of market power among leading firms [5] Internationalization Strategies - Leading companies are shifting from "product export" to "platform export," while smaller firms are adopting the NewCo model to reduce reliance on single markets [6] - Recommendations include establishing cross-border platforms to provide comprehensive support for international expansion and fostering patient capital to better integrate financial resources with technological innovation [6]

Core Insights - The innovative drug market in China is experiencing significant growth, with the total amount of License out transactions for innovative drugs expected to reach nearly $66 billion by the first half of 2025, surpassing the total BD transaction amount for 2024 [1] - The immune system drug market is the second largest prescription drug market globally, with an increasing share of BD transactions, particularly in the autoimmune disease sector, which is gaining attention due to unmet medical needs [2][23] - The emergence of bispecific antibodies (dual antibodies) in the autoimmune disease field is anticipated to create new blockbuster drugs, as they can target multiple antigens simultaneously, enhancing treatment efficacy [7][8][23] Group 1: Market Dynamics - The market for autoimmune disease treatments is projected to reach $119.35 billion by 2027, driven by high demand and long treatment cycles for conditions like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) [2] - The TNFα inhibitors, particularly AbbVie's Humira, have generated over $200 billion in revenue over its lifecycle, showcasing the potential for successful drug development in the immune market [2][4] - The competition in the immune drug market is intensifying, with a growing number of patented drugs and a shift towards precision medicine in clinical and commercial strategies [5] Group 2: Bispecific Antibodies - Bispecific antibodies are gaining traction in autoimmune disease treatment, with the ability to simultaneously target different antigens, potentially leading to more effective disease management [7][8] - Clinical data from Roche's bispecific antibody shows significant efficacy in treating refractory SLE patients, indicating the potential of this class of drugs in the autoimmune sector [8] Group 3: Company Insights - Kangnuo Pharmaceutical is positioned as a leading player in the autoimmune field, with its core product CM310 being the first domestically approved IL-4Rα antibody, currently in the commercialization stage [13][23] - The success of CM310 in the market is contingent on its inclusion in the medical insurance negotiation, which is crucial for its sales growth [16][23] - Kangnuo's innovative approach through the NewCo model for licensing out its products has proven beneficial, providing cash flow support and reducing risks for the company [22][23] Group 4: Future Outlook - The potential for Kangnuo's CM310 to achieve significant sales in the Chinese market is optimistic, with projections suggesting it could reach nearly $5 billion by 2030 if it successfully navigates the insurance landscape [23] - The company's advancements in the ADC drug CMG901 for cancer treatment are also noteworthy, with clinical progress ahead of competitors [19][23]

Group 1 - The innovative drug market in China is experiencing a surge, with the total amount of License out transactions for innovative drugs expected to reach nearly $66 billion by the first half of 2025, surpassing the total BD transaction amount for 2024 [1] - The immune system drug market is the second largest prescription drug market globally, with an increasing proportion of BD transactions. The share of tumor pipeline overseas licensing transactions decreased from 72% in 2023 to 61% in 2024, while the share of metabolic and autoimmune drugs increased from 12% to 25% [1][2] - The autoimmune disease market is gaining attention due to its large unmet medical needs, with the global treatment market projected to reach $119.35 billion by 2027 [2] Group 2 - The immune drug market has evolved since the introduction of TNFα inhibitors, with new targets emerging, including interleukin classes and JAK/Tyk2 inhibitors. The competition in clinical and commercial stages is intensifying, with a focus on precision treatment [5][7] - Bispecific antibody drugs are gaining traction in the treatment of autoimmune diseases, offering the ability to target two different antigens simultaneously, which may lead to more effective disease management [7][8] - The first bispecific antibody drugs in the autoimmune field are expected to create a new wave of growth, with companies like 康诺亚 leading the development [23] Group 3 - 康诺亚's core product, CM310, is the first domestically approved IL-4Rα antibody drug, with significant market potential in treating various allergic diseases. Its success in entering the medical insurance negotiation at the end of the year is crucial for its market performance [13][16] - The company has a strong pipeline in the autoimmune field, with CM310 expected to generate substantial sales, potentially reaching 5 billion yuan by 2030 [23] - 康诺亚 is also advancing in the oncology sector with its ADC drug CMG901, which is in the lead for clinical development among competitors [19][23] Group 4 - 康诺亚 has successfully engaged in multiple NewCo agreements, indicating its potential for international expansion and valuation growth in the innovative drug sector [22] - The NewCo model provides a favorable environment for domestic biotech companies, allowing them to secure cash flow and mitigate risks while advancing their research and clinical trials [22] - The recent licensing deal with GSK, which includes a $500 million upfront payment and up to $12 billion in milestone payments, highlights 康诺亚's strong position in the market [12]

Investment Rating - The report indicates a positive outlook for the autoimmune therapy market, suggesting significant growth potential and investment opportunities in the sector [8]. Core Insights - The autoimmune market is the second largest after oncology, with a global market size of $132.3 billion in 2022, projected to reach $176.7 billion by 2030, reflecting a compound annual growth rate (CAGR) of 3.68% from 2022 to 2030 [8]. - The report highlights the potential for multi-target interventions to enhance treatment efficacy in autoimmune diseases, transitioning from monoclonal antibodies to bispecific and multispecific antibodies [19]. - The report emphasizes the significant market space for autoimmune therapies in China, where the autoimmune market size was only $2.9 billion in 2022, representing just 8% of the oncology market size of $34.7 billion, indicating substantial room for growth [8]. Market Overview - The global autoimmune drug market is expected to grow significantly, with the market size projected to increase from $1,323 million in 2022 to $1,767 million by 2030 [8]. - The report provides a detailed analysis of various autoimmune diseases, their prevalence, and the corresponding patient populations globally, including conditions like atopic dermatitis, chronic obstructive pulmonary disease, and rheumatoid arthritis [6][11]. Clinical Research Progress - The report outlines advancements in clinical research for dual-target and multi-target therapies, indicating a shift towards more effective treatment options for complex autoimmune diseases [19][22]. - It discusses the development of several blockbuster monoclonal antibody drugs in the autoimmune sector, with projected sales for top drugs in 2024, including Dupilumab at $14.15 billion and Risankizumab at $11.72 billion [9]. Key Companies to Watch - The report identifies key companies involved in the development of autoimmune therapies, including Sanofi, AbbVie, and Johnson & Johnson, highlighting their leading products and market positions [9][25].